Orthofix Medical (OFIX)
(Delayed Data from NSDQ)
$14.52 USD
+0.23 (1.61%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $14.54 +0.02 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
OFIX 14.52 +0.23(1.61%)
Will OFIX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for OFIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OFIX
Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up
Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures
OFIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Orthofix (OFIX) Could Rally 72.19%: Here's is How to Trade
Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut
Does Orthofix (OFIX) Have the Potential to Rally 78.73% as Wall Street Analysts Expect?
Other News for OFIX
Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer
Orthofix names Lucas Vitale chief people, business operations officer
Orthofix Medical Inc (OFIX) Reports Significant Sales Growth and Improved EBITDA in Q4 and Full ...
New Debt & Financing Risk for Orthofix International – What’s the Latest?
Orthofix price target raised by $3 at Roth MKM, here's why